Gout: Symptoms, Causes, Uric Acid Levels and Complete Treatment Guide
- Dr. Ryan Heals, Pharm.D.
- 6 days ago
- 11 min read
Gout is the most common form of inflammatory arthritis in the United States — and one of the most painful. According to the latest 2026 data from the Annals of Internal Medicine, gout affects approximately 5.1% of the US population — around 12.1 million adults. It is the most common inflammatory arthritis in men, with prevalence of 5.9% in men versus 2% in women. The frequency of gout in individuals above the age of 80 is 30-fold higher than in those aged 20–29.
Despite being one of the oldest recorded diseases in history — described in ancient Egyptian medical texts and once called the "disease of kings" due to its association with rich food and alcohol — gout is also one of the most treatable. With the right understanding of uric acid management, dietary changes, and medication, the vast majority of gout patients can achieve complete control of their disease and prevent future flares entirely.
What makes gout particularly important in 2026 is its growing recognition as a systemic disease — not just a joint condition. Gout is strongly associated with cardiovascular disease, chronic kidney disease, hypertension, type 2 diabetes, and metabolic syndrome. A gout flare, per a 2022 JAMA study, is itself associated with a significantly increased risk of subsequent cardiovascular events in the days following the attack.
This complete guide covers the biology of gout, how to recognise it, what causes uric acid to rise, how it is diagnosed, the full treatment approach for acute flares and long-term prevention, and the dietary changes that make the biggest difference.
The NIAMS provides comprehensive gout information at: https://www.niams.nih.gov/health-topics/gout
What is Gout? — The Crystal-Driven Mechanism
Gout occurs when uric acid — a waste product produced during the breakdown of purines (found naturally in the body and in certain foods) — accumulates to levels that exceed its solubility in blood and tissue fluids.
When serum urate exceeds the saturation threshold of approximately 6.8 mg/dL, monosodium urate (MSU) crystals begin to form and deposit in joints, tendons, bursae, and surrounding soft tissues. These needle-shaped crystals trigger an intense inflammatory response when disturbed — white blood cells (neutrophils) engulf the crystals, releasing a cascade of inflammatory cytokines (particularly IL-1 beta) that causes the rapid, severe joint inflammation characteristic of a gout attack.
90% of people with gout have kidneys that don't adequately remove uric acid — a problem of under-excretion. Only 10% overproduce uric acid. This distinction matters for treatment: most patients benefit primarily from improving uric acid excretion (or reducing production with xanthine oxidase inhibitors).
Key uric acid thresholds:
Normal serum urate: below 6.0 mg/dL in women; below 7.0 mg/dL in men
Saturation threshold: 6.8 mg/dL — above this, crystal formation becomes possible
Treatment target for gout: below 6.0 mg/dL (ACR 2020 guidelines); below 5.0 mg/dL for patients with tophi
Hyperuricemia definition: above 6.8 mg/dL (some guidelines use 7.0 mg/dL for men)
The Four Stages of Gout
Gout progresses through four recognisable clinical stages if untreated:
Stage 1 — Asymptomatic hyperuricemia:
Elevated serum urate without symptoms. May persist for years or decades. Uric acid levels are elevated (above 6.8 mg/dL) but crystals have not yet triggered inflammation. Most people with hyperuricemia never develop gout — but the higher and more prolonged the elevation, the greater the risk.
Stage 2 — Acute gout flare:
The classic presentation. MSU crystals in a joint provoke sudden, intense inflammatory arthritis. The attack typically reaches maximum intensity within 12–24 hours of onset and resolves spontaneously within 7–14 days without treatment (though treatment significantly reduces duration and severity). The joint is exquisitely tender — even the weight of a bedsheet is unbearable for some patients.
Stage 3 — Intercritical gout:
The periods between gout attacks. The joint appears normal and the patient is asymptomatic. However, MSU crystals remain in the joint and sub-clinical inflammation continues. Without urate-lowering therapy, the next flare becomes more likely and may involve additional joints.
Stage 4 — Chronic tophaceous gout:
Develops after years of uncontrolled hyperuricemia. MSU crystals accumulate as visible deposits (tophi) — typically in the ear cartilage, elbows, Achilles tendon, fingers, and around affected joints. Tophi cause joint destruction, chronic pain, and significant disability. Represents a preventable failure of long-term urate management.
Symptoms — What a Gout Attack Feels Like
A gout flare is one of the most distinctive and recognisable presentations in all of medicine:
Classic features:
Sudden onset
often waking the patient from sleep in the early morning hours (when body temperature is lowest and crystal formation is most likely)
Intense, severe joint pain
often described as the worst pain ever experienced; the affected joint becomes acutely inflamed
Redness and warmth
the skin over the joint becomes bright red, hot, and swollen
Extreme tenderness
even light touch or contact with bedding is intolerable
Swelling
sometimes dramatic, involving the whole joint and surrounding tissue
Peak intensity within 12–24 hours
then gradually resolving over 7–14 days
Most common joints affected:
First metatarsophalangeal joint (base of the big toe) — the most common first joint in 50% of cases; known medically as podagra. Named after the Greek goddess of foot torture — a vividly accurate term.
Ankle — second most commonly affected
Knee — particularly in women and older patients
Wrist, elbow, and finger joints — typically in later disease
Rarely: spine, hip, shoulder (atypical gout)
Warning signs of gout flare (many patients learn to recognise a prodrome):
Slight aching or stiffness in the joint hours before full attack
Local skin tingling or sensitivity
Low-grade fever
Tophi (chronic tophaceous gout signs):
Painless or mildly tender firm lumps under the skin — typically yellowish-white
Common on the helices of ears, elbows, Achilles tendons, fingers
May discharge chalky white material (urate crystals)
What Causes Uric Acid to Rise? — Risk Factors
Multiple factors drive uric acid elevation — dietary, metabolic, medication-related, and genetic:
Dietary and lifestyle causes:
Purine-rich foods
red meat (especially organ meats: liver, kidney, sweetbreads), shellfish (particularly prawns, mussels, scallops), oily fish (sardines, anchovies, mackerel), and game meats are the highest purine sources
Fructose and sugar-sweetened beverages
fructose metabolism directly increases uric acid synthesis; high-fructose corn syrup in sodas is a major and underappreciated driver of gout
Alcohol
particularly beer (high in purines from yeast) and spirits; wine has a lesser effect
Dehydration
reduces renal uric acid excretion
Medical conditions and medications:
Hypertension
strongly associated; diuretics are the most common medication cause of gout
Chronic kidney disease
reduced renal uric acid excretion; major driver of gout in older adults
Obesity and metabolic syndrome
insulin resistance impairs renal uric acid excretion
Type 2 diabetes
bidirectional relationship with hyperuricemia
Diuretics (thiazides, loop diuretics)
the most important medication cause; raise urate significantly by reducing renal excretion; a major reason gout is increasing in elderly women on diuretics for hypertension
Low-dose aspirin
raises urate by competing with uric acid for tubular secretion
Ciclosporin
major cause of gout in transplant recipients
Tacrolimus, pyrazinamide, ethambutol, levodopa
all raise urate levels
Genetic factors:
Gout has a significant genetic component — variants in urate transporter genes (ABCG2, SLC22A12, SLC2A9) account for a substantial proportion of urate variation between individuals. Certain populations have much higher rates — particularly Pacific Islander and Maori populations, and individuals with Lesch-Nyhan syndrome (a rare inherited disorder of purine metabolism producing extreme hyperuricemia).
Diagnosing Gout
Clinical diagnosis vs gold standard:
Gout can often be diagnosed clinically in a classic presentation — sudden podagra in a middle-aged man with hyperuricemia and a typical history. However, the gold standard is joint aspiration (arthrocentesis) with polarised light microscopy showing negatively birefringent needle-shaped MSU crystals.
Key investigations:
Serum urate
elevated (note: may be paradoxically normal or low during an acute flare due to acute-phase cytokine effects on urate handling; do not use a normal urate during a flare to exclude gout)
Full blood count and CRP/ESR
elevated inflammatory markers during a flare
Renal function
essential before starting urate-lowering therapy
Joint aspiration
definitive diagnosis; also excludes septic arthritis which is the most important differential
Dual-energy CT (DECT) scan
non-invasive imaging that can detect and quantify urate deposits; increasingly used in difficult diagnostic cases
Ultrasound
shows "double contour sign" (urate crystal deposition on cartilage surface) highly specific for gout
Treatment — Acute Flare and Long-Term Prevention
Treating gout requires two distinct strategies: treating the acute flare, and long-term urate-lowering therapy to prevent future flares and resolve tophi.
Acute gout flare treatment (start as early as possible):
Colchicine — first-line for acute flare:
Low-dose colchicine (0.5mg twice or three times daily) is the preferred first-line treatment for acute gout in most patients. It works by disrupting the inflammatory cascade triggered by MSU crystals, specifically inhibiting neutrophil migration. Most effective when started within the first 12–24 hours of a flare. Now preferred over high-dose regimens that cause significant gastrointestinal side effects.
NSAIDs — highly effective:
Naproxen, indomethacin, or ibuprofen at full anti-inflammatory doses are very effective for acute gout when started early. Avoid in patients with CKD, peptic ulcer disease, or cardiovascular disease. Note: low-dose aspirin is itself a cause of elevated urate and should not be used for gout analgesia.
Corticosteroids — when colchicine and NSAIDs are contraindicated:
Oral prednisolone (30–35mg daily for 3–5 days) or intra-articular corticosteroid injection for a single joint are effective alternatives — particularly in patients with CKD (where colchicine and NSAIDs need dose adjustment) or on anticoagulants.
IL-1 inhibitors (canakinumab):
For patients with frequent, recurrent flares where standard treatments are contraindicated or ineffective. Canakinumab (IL-1 beta inhibitor) — a single subcutaneous injection produces rapid and sustained flare resolution. Expensive; specialist-initiated.
Long-term urate-lowering therapy (ULT) — for prevention:
When to start: ACR 2020 guidelines recommend starting ULT in all patients who have had 2 or more gout flares per year, tophi, gout-associated joint damage on imaging, or gout with CKD Stage 2 or above.
Allopurinol — first-line ULT:
A xanthine oxidase inhibitor — reduces uric acid production by blocking the enzyme that converts hypoxanthine to xanthine to uric acid. Start at a low dose (50–100mg daily), titrate up every 2–4 weeks to achieve target serum urate below 6.0 mg/dL. Maximum dose 800mg/day. Requires dose adjustment in CKD. HLA-B*5801 testing is recommended before starting allopurinol in patients of Han Chinese, Korean, and Thai ancestry — this allele is associated with severe Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with allopurinol.
Febuxostat — second-line ULT:
A newer, more selective xanthine oxidase inhibitor. More potent than allopurinol at standard doses; useful when allopurinol is not tolerated or is ineffective. FDA-approved but carries a boxed warning for increased cardiovascular mortality in patients with established cardiovascular disease (CARES trial); use with caution in this group.
Probenecid — uricosuric agent:
Increases renal excretion of uric acid. Second-line option when xanthine oxidase inhibitors are contraindicated or not tolerated. Not suitable in patients with CKD or a history of uric acid kidney stones. Risk of stone formation — ensure adequate hydration.
Prophylactic colchicine or NSAID during ULT initiation:
Starting ULT can paradoxically trigger gout flares in the first 3–6 months by mobilising crystal deposits. Low-dose colchicine (0.5mg daily) as anti-inflammatory prophylaxis for the first 3–6 months of ULT significantly reduces this risk and improves treatment adherence.
Gout Medicines Comparison Table
Medicine | Role | Mechanism | Key Notes |
Colchicine (low dose) | Acute flare — first-line | Inhibits neutrophil migration; disrupts IL-1 cascade | Most effective within 12–24 hours; low dose preferred |
Naproxen / Indomethacin | Acute flare — NSAID | Anti-inflammatory prostaglandin inhibition | Avoid in CKD, PUD, cardiovascular disease |
Prednisolone | Acute flare — steroid | Broad anti-inflammatory | Use when colchicine/NSAIDs contraindicated |
Canakinumab | Recurrent flares — biologic | IL-1 beta inhibitor | Specialist use; single injection; expensive |
Allopurinol | ULT — first-line | Xanthine oxidase inhibitor; reduces uric acid production | Start low, titrate; HLA-B*5801 test in Asian patients |
Febuxostat | ULT — second-line | Selective xanthine oxidase inhibitor | More potent than allopurinol; CV warning |
Probenecid | ULT — uricosuric | Increases renal uric acid excretion | Avoid in CKD and kidney stones |
Prophylactic colchicine | ULT initiation cover | Prevents mobilisation flares | Use for first 3–6 months of ULT |
Foods to Avoid and Foods That Help — Gout Diet Table
Food / Drink | Effect on Uric Acid | Recommendation |
Organ meats (liver, kidney, sweetbreads) | Very high purines — major trigger | Avoid completely |
Red meat (beef, lamb, pork) | High purines | Limit to small portions |
Shellfish (prawns, mussels, scallops) | Very high purines | Avoid or strictly limit |
Oily fish (sardines, anchovies, mackerel) | High purines | Limit; omega-3 benefit may partially offset |
Beer | High purines (yeast) + alcohol | Avoid during flares; limit strongly |
Spirits | Raises urate via alcohol metabolism | Limit; avoid during flares |
Wine | Lesser effect than beer | Moderate intake only |
Sugar-sweetened beverages / fruit juices | Fructose directly raises uric acid | Avoid; switch to water |
Low-fat dairy (milk, yogurt) | Uricosuric effect — lowers uric acid | Include daily — protective |
Coffee | Associated with lower uric acid | Up to 4 cups/day may be protective |
Cherries / tart cherry juice | Reduces urate and flare frequency | 1–2 servings daily; evidence-supported |
Water | Increases renal uric acid excretion | 2–3 litres daily — essential |
For our complete guide on chronic kidney disease — a major cause and consequence of gout: [Chronic Kidney Disease: Symptoms, Stages and Treatment]
For our guide on high blood pressure — strongly linked to gout through diuretics and shared metabolic pathways: [High Blood Pressure (Hypertension): Complete Guide]
For our guide on obesity and metabolic syndrome — a major driver of hyperuricemia: [Obesity: Causes, Health Risks and Treatment]
NIH StatPearls gout resource updated April 2026 with current guideline-based management at: https://www.ncbi.nlm.nih.gov/books/NBK546606/
The American College of Rheumatology provides patient-level gout guidance at: https://rheumatology.org/patient-blog/understanding-gout-symptoms-treatment
Frequently Asked Questions
Is gout caused only by eating too much red meat and drinking alcohol?
Diet is an important contributor but explains only part of the picture. While red meat, shellfish, organ meats, alcohol, and fructose-sweetened drinks all raise uric acid, genetics accounts for a substantial proportion of gout risk — variants in urate transporter genes explain much of the variation between individuals. Many people eat a high-purine diet and never develop gout; others develop it despite a relatively healthy diet. Medications — particularly diuretics — and medical conditions including CKD and hypertension are significant non-dietary drivers. Diet modification alone typically reduces serum urate by only 1 mg/dL — most patients with established gout require medication.
Can gout be cured permanently?
Gout cannot be cured, but it can be completely controlled. With consistent urate-lowering therapy achieving serum urate below 6.0 mg/dL maintained long-term, existing MSU crystals gradually dissolve, tophi regress, and gout flares cease entirely. Most patients on effective long-term allopurinol or febuxostat become completely flare-free within 1 to 2 years. The challenge is adherence — stopping ULT causes urate to rise again and flares to recur, making long-term therapy commitment essential.
Why does gout so often attack the big toe?
The first metatarsophalangeal joint (base of the big toe) is affected in approximately 50% of first gout attacks because of its specific anatomical and physiological conditions favouring MSU crystal formation. It is the joint furthest from the heart, meaning it has the lowest local temperature and blood flow. Uric acid solubility decreases dramatically with falling temperature — so the big toe is literally the coldest joint in the body and the most prone to crystal precipitation. The joint also bears tremendous repetitive mechanical stress, and the local pH tends to be lower, both of which further reduce urate solubility.
Should I take allopurinol during a gout flare?
Starting allopurinol or other urate-lowering therapy during an acute flare is controversial — the traditional teaching was to wait until the flare resolves, as changes in urate level can prolong or worsen the attack. However, 2020 ACR guidelines and recent studies support starting ULT during a flare if appropriate flare treatment (colchicine or NSAIDs) is co-administered simultaneously. If already established on allopurinol, it should not be stopped during a flare. The key principle is: never change urate levels rapidly without anti-inflammatory cover.
What is the target uric acid level for gout treatment?
The ACR 2020 guidelines recommend a treatment target of serum urate below 6.0 mg/dL for most gout patients — this is below the saturation threshold of 6.8 mg/dL at which crystals form, allowing existing crystals to gradually dissolve. For patients with tophi or severe gout, a lower target of below 5.0 mg/dL accelerates tophus resolution. The serum urate should be checked every 2 to 4 weeks during ULT dose titration and annually once the target is achieved and stable.
Comments